Chia-Sui Weng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chia-Sui Weng has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chao-Chih Wu
Department of Medical Research, Mackay Memorial Hospital, New Taipei City, Taiwan
1 shared publication - Chih-Long Chang
Department of Obstetrics & Gynecology, MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, Mackay Medical College, Sanzhi, New Taipei City, Taiwan; Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan
1 shared publication Chueh-Yi Huang
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
1 shared publication- Hiroaki Komatsu
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
1 shared publication - Jae-Weon Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
1 shared publication Jen-Ruei Chen
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Asian Young Doctors Session at the 64th Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO): Educational Initiatives in the Next Generation for a New Era after the COVID-19 Pandemic
Kobayashi Y, et al. J Gynecol Oncol. 2022 Nov;34(1):e22. https://doi.org/10.3802/jgo.2023.34.e22
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Open AccessAsian Young Doctors Session at the 64th Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO): Educational Initiatives in the Next Generation for a New Era after the COVID-19 Pandemic
Kobayashi Y, et al. J Gynecol Oncol. 2022 Nov;34(1):e22. https://doi.org/10.3802/jgo.2023.34.e22
- Open Access
- 1 November 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 9899-9905
Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
Purpose: The aim of this study is to analyze the outcomes of platinum-sensitive (PS) recurrent ovarian cancer treated with pegylated liposomal doxorubicin and carboplatin (CD) versus paclitaxel and carboplatin (CP). Clinical features were examined to characterize the patient population that would benefit from CD. Materials and methods: This is a retrospective review of 122 cases at a tertiary hospital. Patients with PS recurrent ovarian cancer who received CD or CP were included. Progression-free survival (PFS) and overall survival (OS) were evaluated through the Kaplan–Meier method and log-rank test. Cox proportional hazards regression was used to examine PFS predictors. Results: In total, 122 patients (75% with first recurrence and 25% with second recurrence) were included. The majority of the patients were diagnosed at an advanced stage and with the histology of serous carcinoma. Median PFS and OS were 14.8 and 55.5 months in the CD group and 13.5 and 56.8 months in the CP group. Subgroup analysis of patients revealed that the CD group had longer median PFS than the CP group among patients with PFI>12 months. Additionally, during the second recurrence, longer PFS was observed in the CD group than in the CP group (medians 22.3 and 13.5 months, respectively, p = 0.019). Conclusion: Comparable outcomes in recurrent platinum-sensitive ovarian cancer treated with CD versus CP were presented in this study. Longer PFS in CD group was observed among patients with PFI for more than 12 months or in second recurrence.
- 1 November 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 9899-9905
Open AccessRetrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
Purpose: The aim of this study is to analyze the outcomes of platinum-sensitive (PS) recurrent ovarian cancer treated with pegylated liposomal doxorubicin and carboplatin (CD) versus paclitaxel and carboplatin (CP). Clinical features were examined to characterize the patient population that would benefit from CD. Materials and methods: This is a retrospective review of 122 cases at a tertiary hospital. Patients with PS recurrent ovarian cancer who received CD or CP were included. Progression-free survival (PFS) and overall survival (OS) were evaluated through the Kaplan–Meier method and log-rank test. Cox proportional hazards regression was used to examine PFS predictors. Results: In total, 122 patients (75% with first recurrence and 25% with second recurrence) were included. The majority of the patients were diagnosed at an advanced stage and with the histology of serous carcinoma. Median PFS and OS were 14.8 and 55.5 months in the CD group and 13.5 and 56.8 months in the CP group. Subgroup analysis of patients revealed that the CD group had longer median PFS than the CP group among patients with PFI>12 months. Additionally, during the second recurrence, longer PFS was observed in the CD group than in the CP group (medians 22.3 and 13.5 months, respectively, p = 0.019). Conclusion: Comparable outcomes in recurrent platinum-sensitive ovarian cancer treated with CD versus CP were presented in this study. Longer PFS in CD group was observed among patients with PFI for more than 12 months or in second recurrence.